Arbutus Biopharma Corp banner

Arbutus Biopharma Corp
NASDAQ:ABUS

Watchlist Manager
Arbutus Biopharma Corp Logo
Arbutus Biopharma Corp
NASDAQ:ABUS
Watchlist
Price: 4.29 USD -3.6% Market Closed
Market Cap: $825.1m

Wall Street
Price Targets

ABUS Price Targets Summary
Arbutus Biopharma Corp

Wall Street analysts forecast ABUS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABUS is 5.78 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

Lowest
Price Target
5.05 USD
18% Upside
Average
Price Target
5.78 USD
35% Upside
Highest
Price Target
7.35 USD
71% Upside
Arbutus Biopharma Corp Competitors:
Price Targets
VINP
Vinci Partners Investments Ltd
46% Upside
BRI
Britania PCL
9% Upside
APA
APA Corp (US)
-29% Downside
NNOX
Nano-X Imaging Ltd
242% Upside
CIGI
Colliers International Group Inc
26% Upside

Revenue
Forecast

-1% / Year
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-1% / Year
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

For the last 14 years the compound annual growth rate for Arbutus Biopharma Corp's revenue is -1%. The projected CAGR for the next 2 years is -20%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-48%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-48%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ABUS's stock price target?
Price Target
5.78 USD

According to Wall Street analysts, the average 1-year price target for ABUS is 5.78 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

What is Arbutus Biopharma Corp's Revenue forecast?
Projected CAGR
-20%

For the last 14 years the compound annual growth rate for Arbutus Biopharma Corp's revenue is -1%. The projected CAGR for the next 2 years is -20%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett